stockrow
Friday 6 November 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
114.36
5.60
+5.15%
Follow INSM
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 4 | 3 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
9.29 | 0.42 | (2.95) | (1.32) | (0.52) | 0.40 | (0.48) | (2.23) | — | — |
P/S ratio |
57.12 | 31.14 | 13.78 | 9.62 | 16.20 | 19.76 | 14.80 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(7.47) | (5.47) | (8.77) | (2.81) | (3.75) | (5.02) | (4.15) | (5.01) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Beneish M-Score |
(1.90) | (2.81) | (2.92) | (2.62) | (2.00) | (3.00) | 8.75 | — | — | — |
P/Operating CF |
(139.89) | (57.79) | (32.14) | (22.88) | (36.30) | (48.65) | (45.48) | (14.38) | — | — |
P/B ratio |
46.87 | 39.69 | 0.00 | 26.83 | 7.44 | 11.78 | 7.72 | 4.84 | — | — |
Price to Tangible BV |
68.56 | 124.98 | 0.00 | 0.00 | 15.23 | 14.34 | 9.71 | 6.74 | — | — |
EV/Sales |
56.05 | 30.91 | 15.13 | 9.69 | 15.54 | 18.86 | 13.92 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(36.35) | (16.44) | (8.61) | (5.93) | (8.06) | (14.14) | (7.58) | (3.25) | — | — |
EV/FCF |
(35.13) | (15.93) | (8.40) | (5.79) | (7.90) | (13.74) | (6.49) | (3.09) | — | — |
Quick Ratio |
3.35 | 4.99 | 3.64 | 6.19 | 5.48 | 4.62 | 5.94 | 6.28 | 8.54 | 5.81 |
Current Ratio |
3.83 | 5.45 | 4.12 | 6.69 | 6.19 | 5.24 | 6.51 | 6.51 | 8.72 | 6.02 |
Net Debt/EBITDA |
0.71 | 0.36 | (0.58) | (0.01) | 0.41 | 0.70 | 0.64 | 0.63 | 1.76 | 0.63 |
Debt/Assets |
24.80% | 55.67% | 88.91% | 69.72% | 46.70% | 46.60% | 47.89% | 52.36% | 12.03% | 23.03% |
Debt/Equity |
0.76 | 3.95 | (3.56) | 13.13 | 1.41 | 1.34 | 1.36 | 1.52 | 0.15 | 0.35 |
Asset Turnover |
0.28 | 0.22 | 0.20 | 0.17 | 0.18 | 0.21 | 0.20 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
0.73 | 0.75 | 0.72 | 0.83 | 0.84 | 0.75 | 0.99 | 0.80 | 0.83 | 0.83 |
Capex/Depreciation |
(1.28) | (1.06) | (0.64) | (0.61) | (0.16) | (0.19) | (1.41) | (0.67) | (0.82) | (1.54) |
Interest Coverage |
(14.88) | (10.34) | (8.69) | (17.29) | (9.27) | (8.97) | (8.49) | (12.07) | (31.89) | (49.57) |
| (249.28%) | 3,926.49% | 614.47% | (193.22%) | (126.66%) | (109.42%) | (108.24%) | (113.92%) | (74.74%) | (75.62%) | |
| (59.53%) | (54.47%) | (50.20%) | (33.21%) | (42.62%) | (38.23%) | (37.77%) | (60.81%) | (55.04%) | (59.30%) | |
ROIC |
0.00% | 0.00% | (633.88%) | (302.28%) | (85.44%) | (145.21%) | (113.35%) | (645.62%) | (332.97%) | (232.15%) |
Return on Tangible Assets |
(89.39%) | (65.07%) | (97.50%) | (42.25%) | (57.58%) | (52.70%) | (47.98%) | (70.21%) | (53.93%) | (117.17%) |
Average Days of Receivables |
84.78 | 52.20 | 49.26 | 44.20 | 47.16 | 36.77 | 51.44 | 204.67 | — | — |
Research and Development Expense of Revenue |
127.15% | 164.52% | 187.09% | 162.02% | 144.72% | 110.18% | 96.51% | 1,477.20% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
115.62% | 126.78% | 112.87% | 108.32% | 124.31% | 123.84% | 154.47% | 1,710.40% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.15 | 0.12 | 0.17 | 0.06 | 0.07 | 0.10 | 0.13 | 0.24 |
Share Based Compensation of Revenue |
25.18% | 26.62% | 24.50% | 23.51% | 24.42% | 21.99% | 19.76% | 266.80% | 0.00% | 0.00% |
Graham Net Nets |
0.01 | (0.01) | (0.17) | (0.13) | 0.00 | 0.03 | 0.04 | 0.12 | — | — |
Graham Number |
0.00 | 0.00 | 16.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(3.68%) | (8.10%) | (17.84%) | (20.33%) | (14.21%) | (9.04%) | (12.73%) | (32.16%) | — | — |
Free Cash Flow Yield |
(2.79%) | (6.23%) | (13.07%) | (17.39%) | (12.13%) | (6.94%) | (14.51%) | (26.87%) | — | — |
Revenue per Share |
3.05 | 2.22 | 2.17 | 1.99 | 1.68 | 1.68 | 1.61 | 0.13 | 0.00 | 0.00 |
Operating CF per Share |
(4.70) | (4.17) | (3.82) | (3.25) | (3.24) | (2.25) | (2.96) | (3.36) | (2.40) | (2.37) |
Capex per Share |
(0.16) | (0.13) | (0.09) | (0.08) | (0.06) | (0.07) | (0.50) | (0.19) | (0.05) | (0.07) |
Free Cash Flow per Share |
(4.86) | (4.30) | (3.91) | (3.33) | (3.31) | (2.32) | (3.46) | (3.55) | (2.44) | (2.44) |
Cash per Share |
7.19 | 8.74 | 5.56 | 9.33 | 6.39 | 5.46 | 5.76 | 6.44 | 5.73 | 2.63 |
Shareholders Equity per Share |
3.71 | 1.74 | (2.36) | 0.71 | 3.66 | 2.83 | 3.09 | 2.71 | 5.42 | 2.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.71 | 1.74 | (2.36) | 0.71 | 3.66 | 2.83 | 3.09 | 2.71 | 5.42 | 2.50 |
Free Cash Flow |
(967.57) | (705.80) | (549.53) | (410.32) | (370.59) | (226.17) | (292.92) | (272.79) | (162.62) | (150.91) |
Working Capital |
1,325.33 | 1,324.13 | 703.43 | 1,083.14 | 701.87 | 504.09 | 469.95 | 439.21 | 344.79 | 140.42 |
Capital Expenditures |
(32.56) | (21.92) | (13.29) | (9.88) | (7.29) | (6.82) | (42.27) | (14.81) | (3.00) | (4.20) |
Net Current Asset Value |
268.63 | (118.19) | (732.70) | (295.10) | 4.00 | 102.62 | 74.57 | 122.66 | 288.46 | 84.93 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.05 | 0.06 | 0.04 | 0.04 | 0.04 | 0.04 | 0.31 | 1.51 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.25 | 0.26 | 0.32 | 0.29 | 0.87 | 0.66 | 0.50 | 0.98 | 0.30 | 0.27 |
Cash ROIC |
(35.43%) | (24.79%) | (33.70%) | (17.16%) | (21.70%) | (19.17%) | (26.52%) | (26.75%) | (20.38%) | (40.58%) |
Accounts Receivable Turnover |
6.29 | 7.80 | 8.61 | 9.08 | 9.21 | 9.19 | 11.03 | 2.91 | — | — |
Accounts Payable Turnover |
0.33 | 0.34 | 0.33 | 0.36 | 0.53 | 1.42 | 1.57 | 0.15 | 0.23 | 0.27 |
Inventory Turnover |
1.07 | 0.94 | 0.86 | 0.81 | 0.76 | 1.02 | 1.37 | 0.14 | 0.00 | 0.00 |
Average Days of Payables |
1,354.03 | 1,214.12 | 1,196.69 | 1,205.83 | 1,033.61 | 392.29 | 198.75 | 2,672.50 | 1,845.89 | 1,562.85 |
Days of Inventory on Hand |
392.11 | 419.64 | 463.38 | 462.97 | 553.96 | 453.98 | 426.82 | 1,059.30 | 0.00 | 0.00 |
Average Receivables |
96.43 | 46.60 | 35.45 | 27.03 | 20.46 | 17.90 | 12.37 | 3.38 | — | — |
Average Payables |
370.63 | 250.10 | 198.55 | 153.57 | 83.94 | 28.02 | 15.46 | 16.21 | 12.56 | 8.95 |
Average Inventory |
115.32 | 90.91 | 76.59 | 68.47 | 58.30 | 38.95 | 17.67 | 17.50 | — | — |
Average Assets |
2,144.89 | 1,677.53 | 1,493.14 | 1,449.97 | 1,019.83 | 769.23 | 673.43 | 533.30 | 350.00 | 297.26 |
Average Common Equity |
512.18 | (23.27) | (121.99) | 249.21 | 343.18 | 268.78 | 234.97 | 284.66 | 257.77 | 233.09 |
Columns are period end dates · fundamentals updated 2 Nov 2026